Shanghai Shyndec Pharmaceutical Co Ltd Market Cap ($1.63 Billion)
Market Cap & Net Worth: Shanghai Shyndec Pharmaceutical Co Ltd (600420)
Shanghai Shyndec Pharmaceutical Co Ltd market cap. Shanghai Shyndec Pharmaceutical Co Ltd (SHG:600420) has a market capitalization of $1.63 Billion (CN¥11.12 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #6670 globally and #1326 in its home market, demonstrating a 2.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Shyndec Pharmaceutical Co Ltd's stock price CN¥8.29 by its total outstanding shares 1341172692 (1.34 Billion). Also see 600420 cash flow metrics for how efficiently the company converts equity into cash flow.
Shanghai Shyndec Pharmaceutical Co Ltd Market Cap History (2015–2026)
Shanghai Shyndec Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows change from $3.39 Billion to $1.63 Billion (-5.61% CAGR). Check 600420 stock price for real-time trading data and today's change.
Shanghai Shyndec Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Shyndec Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 600420 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.21x
Shanghai Shyndec Pharmaceutical Co Ltd's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.10x
Shanghai Shyndec Pharmaceutical Co Ltd's market cap is 2.10 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.03 Billion | $9.13 Billion | $476.93 Million | 0.33x | 6.34x |
| 2017 | $2.36 Billion | $8.52 Billion | $515.80 Million | 0.28x | 4.58x |
| 2018 | $1.70 Billion | $11.32 Billion | $705.52 Million | 0.15x | 2.42x |
| 2019 | $1.69 Billion | $12.20 Billion | $656.37 Million | 0.14x | 2.57x |
| 2020 | $1.81 Billion | $12.56 Billion | $648.79 Million | 0.14x | 2.79x |
| 2021 | $2.00 Billion | $13.94 Billion | $568.28 Million | 0.14x | 3.51x |
| 2022 | $1.77 Billion | $12.96 Billion | $627.79 Million | 0.14x | 2.82x |
| 2023 | $1.92 Billion | $12.07 Billion | $691.88 Million | 0.16x | 2.78x |
| 2024 | $2.34 Billion | $10.94 Billion | $1.08 Billion | 0.21x | 2.16x |
| 2025 | $1.98 Billion | $9.36 Billion | $944.38 Million | 0.21x | 2.10x |
Competitor Companies of 600420 by Market Capitalization
Companies near Shanghai Shyndec Pharmaceutical Co Ltd in the global market cap rankings as of November 8, 2026. Also see Shanghai Shyndec Pharmaceutical Co Ltd (600420) total assets for a full breakdown of the balance sheet.
Key companies related to Shanghai Shyndec Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #530 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #567 globally with a market cap of $47.07 Billion USD ( CN¥321.69 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #609 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #530 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.61 |
| #567 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $47.07 Billion | CN¥50.43 |
| #609 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.80 |
Market Capitalization of Shanghai Shyndec Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Shanghai Shyndec Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Shanghai Shyndec Pharmaceutical Co Ltd's market cap moved from $3.39 Billion to $ 1.63 Billion, with a yearly change of -5.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.63 Billion | -17.92% |
| 2025 | CN¥1.98 Billion | -15.41% |
| 2024 | CN¥2.34 Billion | +21.96% |
| 2023 | CN¥1.92 Billion | +8.55% |
| 2022 | CN¥1.77 Billion | -11.30% |
| 2021 | CN¥2.00 Billion | +10.15% |
| 2020 | CN¥1.81 Billion | +7.48% |
| 2019 | CN¥1.69 Billion | -1.09% |
| 2018 | CN¥1.70 Billion | -27.82% |
| 2017 | CN¥2.36 Billion | -21.98% |
| 2016 | CN¥3.03 Billion | -10.69% |
| 2015 | CN¥3.39 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Shanghai Shyndec Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.63 Billion USD |
| MoneyControl | $1.63 Billion USD |
| MarketWatch | $1.63 Billion USD |
| marketcap.company | $1.63 Billion USD |
| Reuters | $1.63 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and… Read more